NSE: SAILIFE · 11 November 2026
- Sai Life Sciences has risen 19.22% over 3 trading sessions; today's move is +3.50%.
- Sai Life Sciences announced its unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026. Quarterly revenue from operations reached ₹659 crore, marking a 23% increase year-on-year, while EBITDA stood at ₹187 crore with a margin of 28%. For the half year ended 30 September 2026, revenue was reported at ₹1,213 crore with a PAT of ₹172 crore.
- Trading volume was 0.78 times the 20-day average daily volume.
Sai Life Sciences share price: 19.22% rise over 3 trading sessions
Sai Life Sciences Ltd. shares are trading higher by 3.50% at ₹1,901.00 on 11 November 2026, moving near the upper end of the day's range of ₹1,849.30 to ₹1,912.00.
The stock's positive price action contrasts with the Nifty Pharma sector benchmark, which is down 0.52%, while outperforming the broader Nifty index's 1.23% gain. Sai Life Sciences has exhibited strong short-term momentum, registering returns of 22.00% over the past 5 days and 29.21% over the past 20 trading days.
The ongoing market move follows the company's recent release of its financial results for the quarter and half year ended 30 September 2026, alongside continuous investor focus on its expanding contract research, development, and manufacturing operations.
12.55 lakh shares traded by 11 November 2026 · 10:30 AM IST. This compares with a 20-day average daily volume of 16.02 lakh shares (0.78 times). The five-day average daily volume was 49.24 lakh shares. Separately, the NSE report for 9 November 2026 showed 14.45 lakh shares delivered, representing 14.27% of that day’s traded volume. The same report recorded 415,733 trades.
The stock's upward movement aligns with sustained investor interest following its strong second-quarter financial results announced in early November, coupled with outperformance relative to the broader pharma sector.
Latest Company Developments
Sai Life Sciences announced its unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026. Quarterly revenue from operations reached ₹659 crore, marking a 23% increase year-on-year, while EBITDA stood at ₹187 crore with a margin of 28%. For the half year ended 30 September 2026, revenue was reported at ₹1,213 crore with a PAT of ₹172 crore.
Provides a comprehensive view of the company's operational growth across both its CRO and CDMO divisions.
The Board of Directors approved the appointment of new senior management personnel effective 05 November 2026. Mr. Sidhartha Das was appointed as Senior Vice President & Head – Human Resources, Mr. Vijay Kumar Suthari as Vice President – Head Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President – Corporate Communications.
Strengthens core leadership teams across human resources, quality compliance, and corporate communications during a key growth phase.
a press release dated November 05, 2026, titled "Press Release on Financial Results ".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.56% on 30 September 2026. This compares with 29.47% on 30 June 2026, a change of +0.09 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
Maintained a positive stance on Sai Life Sciences with a target price of ₹1,620.
Named Sai Life Sciences a top CRDMO pick, outlining multiple structural growth catalysts.
Historical Bulk / Block Deals
What to Watch Next
- Execution of the ongoing capital expenditure program and capacity ramp-up
- Progress of development and commercial pipelines across CRO and CDMO segments
- Q3 FY27 financial performance and management commentary on margin sustainability
- Delivery volume trends and cash market participation levels
Other Dated Coverage
- Sai Life Sciences Share Price Today: Rises 15.21% in 2 Trading Sessions | 9 November 2026 — 9 November 2026
- Sai Life Sciences Share Price Today: Rises 15.46% in 2 Trading Sessions | 6 November 2026 — 6 November 2026
- Sai Life Sciences Share Price Today: Why SAILIFE Is Rising 1.03% | 3 November 2026 — 3 November 2026
More Sai Life Sciences news and dated analysis →
Frequently Asked Questions
What is the latest Sai Life Sciences company news?
Sai Life Sciences announced its unaudited standalone and consolidated financial results for the second quarter and half year ended 30 September 2026. Quarterly revenue from operations reached ₹659 crore, marking a 23% increase year-on-year, while EBITDA stood at ₹187 crore with a margin of 28%. For the half year ended 30 September 2026, revenue was reported at ₹1,213 crore with a PAT of ₹172 crore.
How strong was Sai Life Sciences’s trading volume?
12.55 lakh shares traded, 0.78 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 10:30 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.